scholarly journals The Effectiveness of Probiotic Lactobacillus rhamnosus and Lactobacillus casei Strains in Children with Atopic Dermatitis and Cow’s Milk Protein Allergy: A Multicenter, Randomized, Double Blind, Placebo Controlled Study

Nutrients ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 1169
Author(s):  
Bożena Cukrowska ◽  
Aldona Ceregra ◽  
Elżbieta Maciorkowska ◽  
Barbara Surowska ◽  
Maria Agnieszka Zegadło-Mylik ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Lactobacillus Casei ◽  
Milk Protein ◽  
Lactobacillus Rhamnosus ◽  
Cow’S Milk ◽  
Controlled Study ◽  
Symptom Improvement ◽  
Cow's Milk ◽  
Probiotic Preparation ◽  
Cow’S Milk Protein

Probiotics seem to have promising effects in the prevention and treatment of allergic conditions including atopic dermatitis (AD) and food allergy. The purpose of this multicenter randomized placebo-controlled trial was to evaluate the effectiveness of a probiotic preparation comprising Lactobacillus rhamnosus ŁOCK 0900, Lactobacillus rhamnosus ŁOCK 0908, and Lactobacillus casei ŁOCK 0918 in children under 2 years of age with AD and a cow’s milk protein (CMP) allergy. The study enrolled 151 children, who—apart from being treated with a CMP elimination diet—were randomized to receive the probiotic preparation at a daily dose of 109 bacteria or a placebo for three months, with a subsequent nine-month follow-up. The primary outcomes included changes in AD symptom severity assessed with the scoring AD (SCORAD) index and in the proportion of children with symptom improvement (a SCORAD score decreased by at least 30% in comparison with that at baseline). After the three-month intervention, both the probiotic and placebo groups showed a significant (p < 0.0001) decrease in SCORAD scores, which was maintained nine months later. The percentage of children who showed improvement was significantly higher in the probiotic than in the placebo group (odds ratio (OR) 2.56; 95% confidence interval (CI) 1.13–5.8; p = 0.012) after three months. Probiotics induced SCORAD improvement mainly in allergen sensitized patients (OR 6.03; 95% CI 1.85–19.67, p = 0.001), but this positive effect was not observed after nine months. The results showed that the mixture of probiotic ŁOCK strains offers benefits for children with AD and CMP allergy. Further research is necessary to assess the effect of probiotic supplementation on the development of immune tolerance. (ClinicalTrials.gov NCT04738565)

scholarly journals ASSESSMENT OF CLINICAL-IMMUNOLOGICAL EFFECTIVENESS OF COMPLEX THERAPY OF INFANT ATOPIC DERMATITIS

2013 ◽  
Vol 10 (5) ◽  
pp. 55-60
Author(s):  
S N Denisova ◽  
T B Sentsova ◽  
M Y Belitskaya
Keyword(s):  
Atopic Dermatitis ◽  
Milk Protein ◽  
Protein Hydrolysate ◽  
Blood Stream ◽  
Diet Therapy ◽  
Cow’S Milk ◽  
Cow's Milk ◽  
Complex Therapy ◽  
Specific Igg ◽  
Cow’S Milk Protein

The work is aimed at assessment of clinicalimmunological effectiveness of diet therapy based on hypoallergenic formula used for infants with atopic dermatitis. 167 infants with atopic dermatitis associated with cow’s milk protein allergy have been put included under outpatient observation. 52 infants of from the first group were being fed on whole goat milk’s formula, 56 infants of from the the second group — cows’ milk protein hydrolysate and 59 infants of the from the third groupsoy’s isolate formula. The age of infants was 2, 5—9 months. The duration of observation was 3—12 months. Complex therapy has been conducted over the infants and it contained antiallergenic treatment and diet therapy with hypoallergenic baby formula. The majority of patients showed improvement due to applied treatment. The first group’s infants with positive clinical dynamic showed decrease of specific IgG and IgE to cow’s milk protein, casein, β-LH and soy’s protein. The infants of the second and third groups also showed decrease of specific IgG and IgE to cow’s milk protein, casein, β-LH, soy’s protein and goat’s milk at clinical remission. All the infants with positive clinical effect showed trend to decrease of IL12, IL13, sICAM1 and sEselectin’s concentration in the blood stream, that can indicate on leukocyte adherence inhibition and cell migration to the area of inflammation. Based on the results of research, we can conclude that replacement of one product with another one by taking into account their clinicalimmunological effectiveness as the method of treatment the of atopic dermatitis patients let us optimize infant diet therapy.

Clinical effectiveness of amino acid formula in infants with severe atopic dermatitis and cow's-milk protein allergy

2016 ◽  
Vol 91 (6) ◽  
pp. 521-527
Author(s):  
Serhiy Nyankovskyy ◽  
Olena Nyankovska ◽  
Dmytro Dobryanskyy ◽  
Oleg Shadrin ◽  
Viktoria Klimenko ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Amino Acid ◽  
Milk Protein ◽  
Clinical Effectiveness ◽  
Cow’S Milk ◽  
Severe Atopic Dermatitis ◽  
Cow's Milk ◽  
Cow’S Milk Protein ◽  
Amino Acid Formula

Allergy to cow’s milk protein

2016 ◽  
Vol 7 (3) ◽  
pp. 153-156 ◽  
Author(s):  
Natalia B Platonova
Keyword(s):  
Atopic Dermatitis ◽  
Food Allergy ◽  
Milk Protein ◽  
Clinical Manifestations ◽  
Allergic Diseases ◽  
Maternity Hospital ◽  
Cow’S Milk ◽  
Cow's Milk ◽  
Cow’S Milk Protein ◽  
Inhalant Allergens

The prevalence of allergic diseases is increasing year by year. Atopic dermatitis (AD) - the earliest clinical manifestation of atopy. By definition, atopic dermatitis is the allergic skin disease that occurs usually in early childhood in individuals with hereditary predisposition to atopic diseases having a chronic relapsing course, age characteristics of the location and morphology of the foci of inflammation, characterized by pruritus and caused hypersensitivity as to allergens, and to nonspecific irritants. Food and inhalant allergens play an important role in the formation of atopic dermatitis. The protein of cow’s milk is one of the first products to which developing sensitization. This is especially important for children in their first year of life. During this period neonatologists of the maternity hospital and precinct pediatricians are very important to assess the risk of a child’s food allergy and, if necessary, artificial feeding or supplementary feeding to recommend an artificial mixture, taking into account evaluation results. The proper purpose depends largely on whether the risk is realized or not, as well as the effectiveness of treatment in the presence of existing clinical manifestations, because a rational diet is the guiding principle of therapy of atopic dermatitis in infants. Unfortunately, precinct pediatricians do not always assess the situation correctly. The article gives a clinical case, an example of which analyzed the most typical errors made when bottle-fed infants with food allergy to cow’s milk protein.

scholarly journals O5 The prevalence of cow’s milk protein allergy in infants with gastroschisis and intestinal failure type 2 and 3

2021 ◽  
Author(s):  
Kornilia Nikaki ◽  
Tracey Johnson ◽  
Haidee Norton ◽  
Gabis Chana ◽  
Amrita Garcha ◽  
...  
Keyword(s):  
Milk Protein ◽  
Intestinal Failure ◽  
Cow’S Milk ◽  
Cow's Milk ◽  
Failure Type ◽  
Cow’S Milk Protein

scholarly journals Fecal Calprotectin and Eosinophil-Derived Neurotoxin in Children with Non-IgE-Mediated Cow’s Milk Protein Allergy

2021 ◽  
Vol 10 (8) ◽  
pp. 1595
Author(s):  
María Roca ◽  
Ester Donat ◽  
Ana Rodriguez Varela ◽  
Eva Carvajal ◽  
Francisco Cano ◽  
...  
Keyword(s):  
Milk Protein ◽  
Statistical Significance ◽  
Functional Gastrointestinal Disorders ◽  
Fecal Calprotectin ◽  
Cow’S Milk ◽  
Cow's Milk ◽  
Young Infants ◽  
Healthy Infants ◽  
Ige Mediated ◽  
Cow’S Milk Protein

Our aim is to assess the efficacy of fecal calprotectin (fCP) and fecal eosinophil-derived neurotoxin (fEDN) as diagnostic markers of cow’s milk protein allergy (CMPA) and for monitoring the infants’ response to a non-IgE mediated cow’s milk protein (CMP)-free diet. We prospectively recruited infants aged 0 to 9 months. Stool samples were taken from 30 infants with CMPA, 19 with mild functional gastrointestinal disorders, 28 healthy infants, and 28 children who presented mild infections. Despite the fact that levels of fCP and fEDN in CMPA infants were higher than in healthy infants at month 0, differences for both parameters did not reach statistical significance (p-value 0.119 and 0.506). After 1 month of an elimination diet, no statistically significant differences in fCP with basal levels were found (p-values 0.184) in the CMPA group. We found a high variability in the fCP and fEDN levels of young infants, and discrepancies in individual behavior of these markers after a CMP-free diet was started. It seems that neither fCP nor fEDN levels are helpful to discriminate between healthy infants and those with signs or symptoms related to non-IgE-mediated CMPA. Additionally, it is debatable if on an individual basis, fCP or fEDN levels could be used for clinical follow-up and dietary compliance monitoring. However, prospective studies with larger populations are needed to draw robust conclusions.

Sign in / Sign up

Export Citation Format

Share Document